Procedure guidelines for MIBG-scintigraphy in children;Leitlinie zur MIBG-szintigraphie bei kindern

NuklearMedizin

Volumn 47, Issue 3, 2008, Pages 132-138

  Franzius, Christiane ^a,d   Schmidt, M ^b   Hero, B ^e   Pfluger, T ^c   Hahn, K ^c  

^a Kliniken und Polikliniken für Nuklearmedizin

^b Kliniken und Polikliniken für Nuklearmedizin   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MR und PET/CT Zentrum Bremen Mitte   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Childhood; Guideline; MIBG scintigraphy; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; IODINE 123;

HEALTH CARE ORGANIZATION; NEUROBLASTOMA; PRACTICE GUIDELINE; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; CHILD; HEMATOLOGIC NEOPLASMS; HUMANS; NEUROBLASTOMA; PHEOCHROMOCYTOMA; PRACTICE GUIDELINES AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 45849099084     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0311     Document Type: Review

References (60)

1. Diagnostische Referenzwerte in der Nuklearmedizin. Empfehlungen der Strahlenschutzkommission - Verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000. 2000;
2. Bonnin F, Lumbroso J, Tenenbaum F et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35: 803-810.
3. Franzius C, Hermann K, Weckesser M et al. Whole-body PET/CT with C-11-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642.
4. Franzius C, Juergens K, Schober O. Is PET/CT necessary in paediatric oncology? For. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
5. Franzius C, Lang K, Wormanns D et al. PET/CT and PET - application in pediatric oncology. Der Nuklearmediziner 2004; 27: 315-323.
6. Franzius C, Riemann B, Vormoor J et al. Metastatic neuroblastoma demostrated by whole-body PET-CT using C-11-HED. Nuklearmedizin 2005; 44: N4-N5.
7. Gelfand M. I-123-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004; 34: 577-579.
8. Gelfand M. Meta-iodobenzylguanidine in children. Semin Nucle Med 1993; 23: 231-242.
9. Gelfand M, Elgazzar A, Kriss V et al. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994; 35: 1753-1757.
10. Geoerger B, Hero B, Harms D et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91: 1905-1913.
11. Giammarile F, Boneu A, Edeline V et al. Guide de realisation de la scintigraphie à la méta-iodobenzylguanidine (mIBG) en oncologie pédiatrique. Med Nucl 2000; 24: 35-41.
12. Giammarile F, Lumbroso J, Ricard M et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high-dose on tumour site detection. Eur J Nucl Med 1995; 22: 1180-1183.
13. Gordon I, Peters A, Gutman A et al. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31: 129-134.
14. Hahn K, Pfluger T. Is PET/CT necassary in paediatric oncology? Against. Eur J Nucl Med Mol Imaging 2006; 33: 966-968.
15. Hero B, Berthold F, Engert H et al. Neuroblastom. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Gesellschaft für Pädiatrische Onkologie und Hämatologie. 2005.
16. Hickeson M, Charron M, Maris J et al. Biodistribution of post-therapeutic versus diagnostic I-131-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004; 42: 268-274.
17. Hoefnagel C, De Kraker J, Valdes Olmos R et al. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (Suppl 1): 61-64.
18. 18F-DOPA whole-body PET - initial results. Radiology 2002; 222: 507-512.
19. Jacobs A, Delree M, Desprechins B et al. Consolidating the role of I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol 1990; 20: 157-159.
20. Kaarsch P, Spix C. Deutsches Kinderkrebsregister, Jahresbericht 2005. Berlin: Buchdruckerei Johannes Krüger OHG 2006.
21. Khafagi F, Shapiro B, Fischer M et al. Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med 1991; 18: 191-198.
22. Khafagi F, Shapiro B, Gross M. The adrenal gland. In: Maisey M, Britton K, Gilday D (eds). Clinical Nuclear Medicine. London: Chapman & Hall 1989; 271-291.
23. Kinnier-Wilson L, Draper G. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 1974; 3: 301-307.
24. Knickmeier M, Schäfers M, Schober O. Two years' experience using no-carrier-added meta-[I-123]iodobenzylguanidine in clincal studies. Eur J Nucl Med 2001; 28: 941.
25. Kushner B, Cheung N. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006; 47: 863-864.
26. Kushner B, Yeh S, Kramer K et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086.
27. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004; 45: 1172-1188.
28. Kushner BH, Yeung HW, Larson SM et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18- fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405.
29. Lassmann M, Biassoni L, Monieurs M et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.
30. Leung A, Shapiro B, Hattner R et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38: 1352-1357.
31. 123I]iodobenzylguanidine uptake in children. Q J Nucl Med 1995; 39: 17-20.
32. Lumbroso J, Guermazi F, Hartmann O et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705.
33. 131I]-metaiodo-benzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991; 35: 220-223.
34. 131I]MIBG) in combination with other agents. Eur J Cancer 1999; 35: 1171-1173.
35. Mairs RJ, Cunningham SH, Russell J et al. Nocarrier-added Iodine-131-MIBG: Evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095.
36. Moyes J, McCready V, Fullbrook A. Neuroblastoma MIBG in its diagnosis and management: Berlin: Springer 1989.
37. Nakajo M, Shapiro B, Copp J et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodo-benzyl-guanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682.
38. Okuyama C, Ushijima Y, Kubota T et al. I-123-Metaiodobenzylguanidine uptake in the nape of the neck of children: likly visualization of brown adipose tissue. J Nucl Med 2003; 44: 1421-1425.
39. Owens J, Bolster AA, Prosser JE et al. No-carrieradded I-123-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 2000; 21: 437-440.
40. Parisi M, Greene M, Dykes T et al. Efficacy of meta iodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992; 27: 768-773.
41. Perel Y, Conway J, Kletzel M et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18.
42. Pfluger T, Schmied C, Porn U et al. Integrated imaging using MRI and I-123-metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnodid of pediatric neuroblastoma. Am J Roentgenol 2003; 181: 1115-1124.
43. Piepsz A, Hahn K, Roca I et al. A radiopharmaceutical schedule for image in pediatric. Recommendations of the pediatric task group of the European Association of Nuclear Medicine. Eur J Nucl Med 1990; 17: 127-129.
44. Pintelon H, Jonckheer M, Piepsz A. Paediatric nuclear medicine procedures: routine sedation or management of anxiety. Nucl Med Commun 1994; 15: 664-666.
45. Rufini V, Fisher G, Shulkin B et al. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37: 1464-1468.
46. 123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 4: 25-28.
47. Schmidt M, Eschner W, Dietlein M et al. Konventionelle nuklearmedizinische Tumordiagnostik (Tumor-SPECT): Was ist angesichts von F-18-FDG-PET noch aktuell? Nuklearmedizin 2005; 44: 37-48.
48. Schmidt M, Simon T, Hero B et al. Is there a benefit of I-131-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151.
49. Shapiro B, Copp J, Sisson J et al. Iodine-131 meta-iodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-585.
50. Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-688.
51. Shulkin BL, Hutchinson RJ, Castle VP et al. Neuro blastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750.
52. Shulkin BL, Koeppe RA, Francis IR et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: Localization with PET and administration of FDG. Radiology 1993; 186: 711-715.
53. Shulkin BL, Wieland DM, Baro ME et al. PET Hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37: 16-21.
54. Shulkin BL, Wieland DM, Schwaiger M et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 1992; 33: 1125-1131.
55. Sisson J, Shulkin B. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43: 217-223.
56. Solanki K, Bomanji J, Moyes J et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta- iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
57. Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112.
58. Trampal C, Engler H, Juhlin C et al. Pheochromocytomas: Detection with C-11 hydroxyephedrine PET. Radiology 2004; 230: 423-428.
59. 131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
60. Young JJ, Ries L, Silverberg E et al. Cancer incidence, survival, and mortality for children younger than age 15years. Cancer 1986; 58 (Suppl 2): 598-602.